Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Arcus Biosciences, Inc.NYSE: RCUS
Deferred Revenue · Q2 FY2026 · quarter ended Jun 2026
Deferred revenue falls 73.2% from a year ago
Deferred revenue stood at $19M at the end of Q2 FY2026, down 73.2% from a year earlier and down 44.1% from the prior quarter. Over 3 fiscal years it compounded at -28.8% a year.
Context
- Deferred revenue amounted to 2.1% of total assets at the end of Q2 FY2026, down 4.5 pp from a year earlier.
- Deferred revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -73.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 35M USD
- Year-over-year change
- -58.8%
- 4-year CAGR
- -23.5%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35M | -58.8% |
| FY2024 | 2024-12-31 | 85M | -6.6% |
| FY2023 | 2023-12-31 | 91M | -6.2% |
| FY2022 | 2022-12-31 | 97M | -4.9% |
| FY2021 | 2021-12-31 | 102M | — |
Deferred Revenue vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's Jun 2026 deferred revenue of $19M is the highest of the 9 companies compared; the peer median is $0.
- Its year-over-year change of -73.2% is the 2nd highest of 4, against a peer median of -100.0%.
- Deferred revenue amounts to 2.1% of total assets for RCUS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $19M | -73.2% | -28.8% | 2.1% | |
| Jun 2026 | $181K | -37.2% | +8.4% | 0.0% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | -100.0% | -63.4% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding RCUS) | $0 | -100.0% | -27.5% | 0.0% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 147.91M | 206M | 127M | 150M | 222M |
| Short-term Investments | 351.39M | 803M | 632M | 828M | 759M |
| Net Receivables | 746.82M | 43M | 42M | 25M | 16M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 14.72M | 14M | 30M | 13M | 10M |
| Total Current Assets | 1.26B | 1.07B | 831M | 1.02B | 1.01B |
| Property, Plant & Equipment (Net) | 137.42M | 135M | 51M | 47M | 40M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 185M | 134M | 107M | 14M | 29M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 7.73M | 10M | 106M | 73M | 63M |
| Total Non-current Assets | 330.15M | 279M | 264M | 134M | 132M |
| Total Assets | 1.59B | 1.35B | 1.1B | 1.15B | 1.14B |
| Account Payables | 10.26M | 20M | 17M | 18M | 42M |
| Short-term Debt | 5.1M | 3M | 0 | 0 | 0 |
| Tax Payables | 1.82M | 0 | 0 | 1M | 0 |
| Deferred Revenue | 102M | 97M | 91M | 85M | 35M |
| Other Current Liabilities | 30.26M | 48M | 39M | 14M | 18M |
| Total Current Liabilities | 166.08M | 193M | 184M | 226M | 231M |
| Long-term Debt | 0 | 0 | 0 | 48M | 99M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 462.22M | 355M | 307M | 234M | 43M |
| Other Non-current Liabilities | 5.26M | 23M | 142M | 157M | 135M |
| Total Non-current Liabilities | 584.36M | 495M | 449M | 439M | 277M |
| Total Liabilities | 750.45M | 688M | 633M | 665M | 508M |
| Common Stock | 7K | 1.21B | 1.31B | 1.62B | 2.12B |
| Retained Earnings | (275.35M) | (542M) | (849M) | (1.13B) | (1.49B) |
| Accumulated OCI | (1.26M) | (7M) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 841.45M | 657M | 462M | 485M | 631M |
| Total Debt | 121.99M | 120M | 11M | 60M | 112M |
| Net Debt | (25.93M) | (86M) | (116M) | (90M) | (110M) |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.